Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma

Li, Xiaocheng; Diao, Wenbin; Xue, Hantao; Wu, Fei; Wang, Weiyu; Jiang, Bin; Bai, Jingkun; Lian, Bo; Feng, Weiguo; Sun, Tao; Yu, Wei; Wu, Jingliang; Qu, Mei-Hua; Wang, Yubing; Gao, Zhiqin

doi:10.1016/j.canlet.2020.06.017

Cited by 47 publications

(38 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anorexia was the most common gastrointestinal disorder in adults (39.9–50.2%), diarrhea was the most common digestive disorder in adults and children (2–49.5%), and vomiting was more common in children, 6.5–66.7% [ 33 ]. Wei et al [ 34 ] reported that among 84 cases, signs and symptoms of COVID-19 were more frequent in patients with diarrhea than in those without diarrhea. These included headache (58% vs 22%), myalgia or fatigue (65% vs 34%), cough (85% vs 45%), expectoration (54% vs 21%), nausea (38% vs 10%) and vomiting (19% vs 2%).…”

Section: Clinical Characteristics Of Covid-19-associated Diarrheamentioning

confidence: 99%

“…Patients with diarrhea had longer hospital stays than patients without (16.5 ± 5.2 vs 11.8 ± 5.6 days). Although the clinical signs and symptoms of these COVID-19 diarrhea patients were severe, there were no differences in laboratory tests such as routine blood and lung imaging between the diarrhea and non-diarrhea groups [ 34 ]. Abdominal imaging results are lacking, but needed.…”

Section: Clinical Characteristics Of Covid-19-associated Diarrheamentioning

confidence: 99%

See 1 more Smart Citation

Attaching clinical significance to COVID-19-associated diarrhea

Wang

Zheng

et al. 2020

Life Sciences

View full text Add to dashboard Cite

The Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), erupted in 2020 and created severe public health and socioeconomic challenges worldwide. A subset of patients, in addition to presenting with typical features such as fever, cough and dyspnea, was also afflicted with diarrhea. However, the clinical features and prognoses related to COVID-19-associated diarrhea have not attracted sufficient attention. This review of the medical literature examines the incidence, pathogenesis, clinical characteristics, fecal virus changes, prognoses and influencing factors of COVID-19-associated diarrhea. The reported incidence of diarrhea in patients with COVID-19 ranged from 2% to 49.5%. The main cause of diarrhea was found to be invasive by SARS-CoV-2 of ACE-2-expressing epithelial cells of the small intestine, causing local intestinal damage. This cellular invasion may be the key factor for the much longer duration of SARS-CoV-2 positivity observed for feces compared to pharyngeal swabs. The associated diarrhea in these patients upsets the balance of intestinal flora, resulting in more-severe disease intensity and worse prognosis. Clinicians should be vigilant to this kind of COVID-19-associated diarrhea, and design more effective prevention and treatment options for patients with positive fecal nucleic acid tests and intestinal microflora disorders.

show abstract

Section: Clinical Characteristics Of Covid-19-associated Diarrheamentioning

confidence: 99%

Section: Clinical Characteristics Of Covid-19-associated Diarrheamentioning

confidence: 99%

Attaching clinical significance to COVID-19-associated diarrhea

Wang

Zheng

et al. 2020

Life Sciences

View full text Add to dashboard Cite

show abstract

“…The results indicated that the fluorescence of FITC-GA-HA in HepG2 was stronger than that in MCF-7 cells. Among these cells, GA-R is widely expressed on human liver cancer HepG2 cells ( 33 , 34 ) . Therefore, GA receptor-mediated endocytosis may be a key mechanism by which GA-HA-NPs target the liver.…”

Section: Discussionmentioning

confidence: 99%

“…In vitro drug release study. The in vitro release of DTX from DTX/GA-HA was investigated using the dialysis diffusion method (32)(33)(34) in PBS (pH 7.4). In brief, 5 ml of DTX/GA-HA NPs was added to a dialysis bag (molecular weight, 3,500 Da).…”

Section: Drug Encapsulation Efficiency (Ee) and Loading Capacity (Lc)mentioning

confidence: 99%

Preparation of docetaxel‑loaded, glycyrrhetinic acid‑modified nanoparticles and their liver‑targeting and antitumor activity

et al. 2021

Self Cite

View full text Add to dashboard Cite

Liver cancer is one of the most common malignancies worldwide and poses a serious threat to human health. The most important treatment method, liver cancer chemotherapy, is limited due to its high toxicity and poor specificity. Targeted drug delivery systems have emerged as novel therapeutic strategies that deliver precise, substantial drug doses to target sites via targeting vectors and enhance the therapeutic efficacy. In the present study, glycyrrhetinic acid-modified hyaluronic acid (GA-HA) was used as a carrier for the model drug docetaxel (DTX) to prepare DTX-loaded GA-HA nanoparticles (DTX/GA-HA-NPs). The results indicated that the DTX/GA-HA-NPs exhibited high monodispersity (particle dispersity index, 0.209±0.116) and desirable particle size (208.73±5.0 nm) and zeta potential (-27.83±3.14 mV). The drug loading capacity and encapsulation efficiency of the NPs were 12.59±0.68 and 85.38±4.62%, respectively. Furthermore, it was determined that FITC-GA-HA was taken up by cells and distributed in the cytoplasm. DTX and DTX/GA-HA (just the DTX delivered by the nanoparticle) aggregated and altered the structure of cellular microtubules. Compared with DTX alone, DTX/GA-HA-NPs had a stronger inhibitory effect on HepG2 cell proliferation and promoted apoptosis of HepG2 cells. All experimental results indicated that DTX/GA-HA-NPs were successfully prepared and had liver-targeting and antitumor activities in vitro , which provided a foundation for future in vivo studies of the antitumor effects of DTX/GA-HA-NPs.

show abstract

“…tems have been proposed to extend the half-life of drugs, increase drug targeting, improve drug bioavailability, and reduce adverse reactions of chemotherapy drugs [16]. Many effective drug delivery vectors, such as liposomes [85], polymer NPs [86], micelles [87], exosomes [88], hydrogels [89], polymersomes [90], and drug-polymer conjugates [91], have been proposed to ensure that two or more drugs are delivered to the tumor site at the same time (Fig. 5) [92].…”

Section: Reviewsmentioning

confidence: 99%

Co-delivery of chemotherapeutic drugs and cell cycle regulatory agents using nanocarriers for cancer therapy

Sun

Jing

et al. 2021

Sci. China Mater.

View full text Add to dashboard Cite

Combination chemotherapy is widely exploited to overcome multidrug resistance (MDR) and enhance the therapeutic effect of anti-tumor agents clinically. The traditional combination regimens applied in clinical practice still suffer from various obstacles, such as inevitable side effects. Fortunately, the application of nanotechnology and the proposal of co-delivery systems make the combination therapy more effective. The occurrence, development, and metastasis of tumors are closely related to the cell cycle. The sensitivity of tumor cells to chemotherapeutic drugs can be improved with the cooperation of cell cycle regulators. In this review, the influence of the cell cycle on tumorigenesis and development is introduced briefly. The current strategies of combining chemotherapeutic drugs and cell cycle regulators through codelivery systems are discussed in detail. We also sketch the possibility of treating tumors mildly via artificially controlling the cell cycle and outline the challenges and perspectives about the improvement of co-delivery systems for cancer therapy.

show abstract

Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma

Cited by 47 publications

References 38 publications

Attaching clinical significance to COVID-19-associated diarrhea

Attaching clinical significance to COVID-19-associated diarrhea

Preparation of docetaxel‑loaded, glycyrrhetinic acid‑modified nanoparticles and their liver‑targeting and antitumor activity

Co-delivery of chemotherapeutic drugs and cell cycle regulatory agents using nanocarriers for cancer therapy

Contact Info

Product

Resources

About